Abstract | BACKGROUND: PATIENTS AND METHODS: Patients received high dose accelerated radiotherapy (66 Gy in 24 fractions) and concurrent daily Cisplatin (6 mg/m(2)) without (Arm A) or with (Arm B) weekly Cetuximab (400 mg/m(2) loading dose one week prior to radiotherapy followed by weekly 250 mg/m(2)). The primary endpoint of the trial was objective local control rate (OLCR) determined at 6-8 weeks after treatment. Toxicity was reported as well. RESULTS: Between February 2009 and May 2011, 102 patients were randomized. Median follow up was 29 months. The OLCR was 84% in Arm A and 92% in Arm B (p=0.36). The one-year local progression free interval (LPFI) and overall survival (OS) were 69% and 82% for Arm A and 73% and 71% for Arm B, respectively (LPFI p=0.39; OS p=0.99). Toxicity compared equally between both groups. CONCLUSION: The addition of Cetuximab to radiotherapy and concurrent Cisplatin did not improve disease control in patients with locally advanced NSCLC but increased treatment related toxicity.
|
Authors | Michel M van den Heuvel, Wilma Uyterlinde, Andrew D Vincent, Jeroen de Jong, Joachim Aerts, Frederike Koppe, Joost Knegjens, Henk Codrington, Peter W E Kunst, Edith Dieleman, Marcel Verheij, José Belderbos |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 110
Issue 1
Pg. 126-31
(Jan 2014)
ISSN: 1879-0887 [Electronic] Ireland |
PMID | 24225233
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Cetuximab
- Cisplatin
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, radiotherapy)
- Cetuximab
- Chemoradiotherapy
- Cisplatin
(administration & dosage, therapeutic use)
- Female
- Humans
- Lung Neoplasms
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Treatment Outcome
|